EV Biologics Corp. announced that it has signed a Letter of Intent (LOI) with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as MSCs.
[EV Biologics Corp. (BioSpace)]
Sorry, but the selected Zotpress account can't be found.
